SURUNKALI BRUTSELLYOZDA REABILITATSIYANING KLINIK-FUNKSIONAL ASOSLARI VA SAMARADORLIGINI BAHOLASHNING ZAMONAVIY YONDASHUVLARI (adabiyotlar sharhi)
Kalit so‘zlar:
brutsellyoz, surunkali brutsellyoz, persistensiya, reabilitatsiya, hayot sifatiAbstrak
Brutsellyoz endemik hududlarda keng tarqalganligi, surunkali kechishga moyilligi hamda barqaror funksional buzilishlar rivojlanishi sababli dolzarb tibbiy-ijtimoiy muammo bo‘lib qolmoqda. Ushbu sharhda surunkali brutsellyozning klinik-patogenetik mexanizmlari, jumladan Brucella spp.ning hujayra ichidagi persistensiyasi va immunoregulyator buzilishlar haqidagi zamonaviy ma’lumotlar tahlil qilindi. Kasallikning klinik polimorfizmi, tayanch-harakat va asab tizimining tez-tez zararlanishi, shuningdek retsidivlanuvchi kechishi bemorlar hayot sifatini sezilarli darajada pasaytirishi ko‘rsatildi. Ta’kidlanishicha, antibakterial terapiya yakunlangandan keyin ham ayrim bemorlarda og‘riq sindromi, asteniya, harakatchanlik cheklanishi va psixoemotsional buzilishlar saqlanib qoladi. Bu holat surunkali brutsellyozli bemorlarni kompleks olib borishda reabilitatsiyani kiritish zarurligini asoslaydi. Funksiyalarni, ijtimoiy faollikni va mehnat qobiliyatini tiklashga qaratilgan multidissiplinar yondashuvga alohida e’tibor qaratilgan. Reabilitatsiya samaradorligini baholashning zamonaviy vositalari, jumladan funksional holat, hayot sifati, og‘riq va jismoniy chidamlilik ko‘rsatkichlari ko‘rib chiqilgan.
Reabilitatsiya tadbirlarini klinik fenotip, cheklanishlar darajasi va retsidiv xavfini hisobga olgan holda algoritmlashtirish maqsadga muvofiq degan xulosaga kelindi.
##plugins.themes.default.displayStats.downloads##
Havolalar
1. World Health Organization. Brucellosis [Internet]. WHO; 2020 (updated 2020 Jul 29) [cited 2026 Feb 24].
2. World Organisation for Animal Health (WOAH). Brucellosis (Chapter 3.1.4; Manual of Diagnostic Tests and Vaccines for Terrestrial Animals) [Internet]. WOAH; 2022–2024 [cited 2026 Feb 24].
3. Centers for Disease Control and Prevention. Brucellosis: About Brucellosis [Internet]. CDC; 2024 [cited 2026 Feb 24].
4. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006;6(2):91–9. doi:10.1016/S1473-3099(06)70382-6.
5. Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. Lancet Infect Dis. 2007;7(12):775–86. doi:10.1016/S1473-3099(07)70286-4.
6. Laine CG, Johnson VE, Scott HM, Arenas-Gamboa AM. Global estimate of human brucellosis incidence. Emerg Infect Dis. 2023;29(9):1789–1797. doi:10.3201/eid2909.230052.
7. Earhart K, Vafakolov S, Yarmohamedova N, Michael A, Tjaden J, Soliman A. Risk factors for brucellosis in Samarqand Oblast, Uzbekistan. Int J Infect Dis. 2009;13(6):749–753. doi:10.1016/j.ijid.2009.02.014.
8. Zinsstag J, Schelling E, Waltner-Toews D, Tanner M. From “one medicine” to “one health” and systemic approaches to health and well-being. Prev Vet Med. 2011;101:148–56.
9. Atluri VL, Xavier MN, de Jong MF, den Hartigh AB, Tsolis RM. Interactions of Brucella spp. with the host immune system. Annu Rev Microbiol. 2011;65:523–41.
10. Celli J, de Chastellier C, Franchini DM, Pizarro-Cerda J, Moreno E, Gorvel JP. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J Exp Med. 2003;198(4):545–56.
11. Ke Y, Wang Y, Li W, Chen Z. Type IV secretion system of Brucella spp. and its effectors. Front Cell Infect Microbiol. 2015;5:72. doi:10.3389/fcimb.2015.00072.
12. Dugelay C, Celli J, Terradot L. The Brucella type IV secretion system and effector proteins. microLife. 2025;6:uqaf036. doi:10.1093/femsml/uqaf036.
13. Pellegrini JM, Gorvel JP, Mémet S. Immunosuppressive mechanisms in brucellosis in light of chronic bacterial diseases. Microorganisms. 2022;10(7):1260. doi:10.3390/microorganisms10071260.
14. Hou S, Kong F, Li X, Xu Y, Chen S, Zhang S, Zhang L, Li T, Fu Y, Li C, Wang W. Role of myeloid-derived suppressor cells in chronic brucellosis. Front Cell Infect Microbiol. 2024;14:1347883. doi:10.3389/fcimb.2024.1347883.
15. Banai M. The myth of Brucella L-forms and possible involvement of L-forms in chronic brucellosis. Med Hypotheses. 2002;59.
16. Mikhaylov LM, Kalinovsky AI, Balakhonov SV, et al. Persistence of L-forms of Brucella in patient with chronic form of brucellosis. Zh Mikrobiol Epidemiol Immunobiol. 2009;86(5):114–115.
17. Roop RM II, Gaines JM, Anderson ES, Caswell CC, Martin DW. Survival of the fittest: how Brucella strains adapt to their intracellular niche. Nat Rev Microbiol. 2009;7:707–15.
18. Dean AS, Crump L, Greter H, Schelling E, Zinsstag J. Clinical manifestations of human brucellosis: a systematic review and meta-analysis (commissioned by WHO). PLoS Negl Trop Dis. 2012;6(12):e1929.
19. Esmaeilnejad-Ganji SM, Esmaeilnejad-Ganji SM. Osteoarticular manifestations of human brucellosis: a review. World J Orthop. 2019;10.
20. Adetunji SA, Ramirez G, Foster MJ, Arenas-Gamboa AM. Prevalence of osteoarticular brucellosis: systematic review and meta-analysis. PLoS Negl Trop Dis. 2019;13(1):e0007112.
21. Spernovasilis N, et al. Brucella spondylitis: current knowledge and recent advances. J Clin Med. 2024;13(2):595.
22. Guven T, et al. Neurobrucellosis: clinical and diagnostic features. Clin Infect Dis. 2013;56(10):1407–12.
23. Jiang W, et al. Epidemiological characteristics, clinical manifestations and outcomes; chronic brucellosis impact on quality of life. BMC Infect Dis. 2019;19.
24. Shayan NA, Rahimi A, Stranges S, Thind A. Quality of life among brucellosis patients in Herat, Afghanistan: case-control study. Infect Ecol Epidemiol. 2025;15(1):2441566. doi:10.1080/20008686.2024.2441566.
25. Alavi SM, Alavi L. Treatment of brucellosis: a systematic review of studies in recent twenty years. Jundishapur J Microbiol. 2013.
26. Maduranga S, et al. A systematic review and meta-analysis of comparative antibiotic regimens for brucellosis. Sci Rep. 2024.
27. Beig M, et al. Cotrimoxazole and rifampin resistance in Brucella: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2024. doi:10.1371/journal.pntd.0012630.
28. Dadar M, et al. Risk factors for brucellosis relapse and focal complications. Int J Infect Dis. 2025.
29. World Health Organization. Rehabilitation [Internet]. WHO; 2019 [cited 2026 Feb 24].
30. World Health Organization. International Classification of Functioning, Disability and Health (ICF) [Internet]. WHO; 2001– [cited 2026 Feb 24].
31. World Health Organization. Rehabilitation in health systems: guide for action. Geneva: World Health Organization; 2019 [cited 2026 Feb 24].
32. World Health Organization. Rehabilitation indicator menu: a tool accompanying the Framework for Rehabilitation Monitoring and Evaluation (FRAME). 2nd ed. Geneva: World Health Organization; 2023 [cited 2026 Feb 24].
33. World Health Organization. Package of Interventions for Rehabilitation (PIR) [Internet]. WHO; 2023 [cited 2026 Feb 24].
34. World Health Organization. WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) [Internet]. WHO; 2010– [cited 2026 Feb 24].
35. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.
36. Huskisson EC. Measurement of pain. Lancet. 1974;2(7889):1127–31.
37. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7. doi:10.1164/ajrccm.166.1.at1102.
38. Singh BB, Khatkar MS, Aulakh RS, Gill JPS, Dhand NK. Estimation of the health and economic burden of human brucellosis in India. Prev Vet Med. 2018;154:148–55. doi:10.1016/j.prevetmed.2018.03.023.
